During GLP-1 medication usage, consumers need to focus on muscle mass retention, minimizing GI discomfort and hydration
Understanding the Role of GLP-1 Agonists In addition to demonstrating weight loss benefits in adults with mood disorders including bipolar disorder, GLP-1 agonists such as liraglutide, tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) have exhibited promising outcomes in addressing commonly associated metabolic concerns
The launch comes amid surging #demand for GLP-1's in South Africa Interest spiked last year following the entry of Eli Lilly and Company's #Mounjaro(#tirzepatide) and Novo Nordisk's own Ozempic
Standard dosing begins at 0.25 mg weekly for four weeks, increasing to 0.5 mg, then potentially 1 mg or 2 mg weekly depending on response and tolerability
Details on withdrawn subjects are provided in Supplementary Figs
There's this sense of urgency that's driving people to make rash decisions, he says